Janssen’s Darzalex (daratumumab) Combination Regimen Receives EC’s Approval for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

 Janssen’s Darzalex (daratumumab) Combination Regimen Receives EC’s Approval for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Janssen’s Darzalex (daratumumab) Combination Regimen Receives EC’s Approval for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Shots:

  • The approval is based on P-III CASSIOPEIA studyassessingDarzalex + bortezomib, thalidomide and dexamethasone (VTd) vs VTd in 1085 newly diagnosed patients with previously untreated, symptomatic MM, who were eligible for high-dose CT and stem cell transplant
  • The P-III CASSIOPEIA study results: higher sCR (29% vs 20%); @18.8mos. improvement in PFS (93% vs 85%), published in The Lancet in Jun’2019 and at ASCO2019. The approval marks the sixth approval for Darzalex and the third in the frontline setting
  • Darzalex is a CD38-directed antibody and is an approved therapy as monothx. or in combination with other drugs in multiple countries including the US for MM. In Aug’2012, Genmab granted exclusive rights of Darzalex to Janssen

Click here ­to­ read full press release/ article | Ref: Business wire  | Image: Janssen

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post